New chemotherapy combinations for advanced bladder cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference33 articles.
1. Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy
2. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach)
3. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation
4. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
5. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN);Annals of Oncology;2017-07
2. Vinflunine as second-line therapy for advanced urothelial carcinoma: Russian observational study;Cancer Urology;2017-01-01
3. First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients;Hematology/Oncology Clinics of North America;2015-04
4. Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents;Critical Reviews in Oncology/Hematology;2009-03
5. Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols;Current Pharmaceutical Design;2007-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3